The Technical Analyst
Generation Bio Co [GBIO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Generation Bio Co Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-8.28% $2.99
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 198.77 mill |
| EPS: | -1.960 |
| P/E: | -1.530 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 66.48 mill |
| Avg Daily Volume: | 0.242 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.530 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.26x |
| Company: PE -1.530 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.238 (-107.97%) $-3.23 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.68 - 3.30 ( +/- 10.40%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Stanton Matthew | Buy | 1 674 | Common Stock |
| 2024-04-15 | Stanton Matthew | Sell | 492 | Common Stock |
| 2024-04-15 | Stanton Matthew | Sell | 1 674 | Restricted Stock Units |
| 2024-04-15 | Samayoa Phillip | Buy | 1 147 | Common Stock |
| 2024-04-15 | Samayoa Phillip | Sell | 337 | Common Stock |
| INSIDER POWER |
|---|
| 82.96 |
| Last 100 transactions |
| Buy: 2 618 558 | Sell: 231 211 |
Forecast:
16:00 - $2.99
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.99
Forecast 2: 16:00 - $2.99
Forecast 3: 16:00 - $2.99
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.99 (-8.28% ) |
| Volume | 0.114 mill |
| Avg. Vol. | 0.242 mill |
| % of Avg. Vol | 47.38 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GBIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:29 | sell | $1.930 | N/A | Active |
|---|
GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-22 17:31:00 - Press Release
Generation Bio Announces The Acceptance Of Five Abstracts And An Invited Oral Presentation At The American Society Of Gene And Cell Therapy (asgct) 27th Annual Meeting
Cambridge, mass., april 22, 2024 (globe newswire) -- generation bio co. (nasdaq:gbio) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctlnp) and immune-quiet dna (iqdna) platforms have been accepted for presentation, including one oral presentation, at the american society of gene and cell therapy (asgct) 27th annual meeting taking place may 7-11, 2024 in baltimore, md.
2024-04-02 06:59:00 - Press Release
Generation Bio To Present At The 23rd Annual Needham Virtual Healthcare Conference
Cambridge, mass., april 02, 2024 (globe newswire) -- generation bio co. (nasdaq:gbio) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that geoff mcdonough, m.d., president and chief executive officer, will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024 at 12:45 p.m. et.
2024-03-06 16:20:00 - Press Release
Generation Bio Reports Business Highlights And Fourth Quarter And Full Year 2023 Financial Results
- company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia
2024-02-27 06:59:00 - Press Release
Generation Bio To Present At The 2024 Td Cowen Health Care Conference
Cambridge, mass., feb. 27, 2024 (globe newswire) -- generation bio co. (nasdaq:gbio) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that geoff mcdonough, m.d., president and chief executive officer, will present at the 2024 td cowen health care conference on tuesday, march 5, 2024 at 9:10 a.m. et in boston.
2024-01-03 16:05:00 - Press Release
Generation Bio To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Cambridge, mass., jan. 03, 2024 (globe newswire) -- generation bio co. (nasdaq:gbio) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that geoff mcdonough, m.d., president and chief executive officer, will present at the 42nd annual j.p. morgan healthcare conference on wednesday, january 10, 2024 at 3:45 p.m. pt in san francisco.
Latest News
2024-03-06 18:41:03 - Zacks Investment Research
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.55 per share a year ago.
2024-02-27 06:59:00 - GlobeNewsWire
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2024 TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 9:10 a.m. ET in Boston.
2024-01-03 16:05:00 - GlobeNewsWire
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 3:45 p.m. PT in San Francisco.
2023-12-07 15:36:49 - PennyStocks
3 Penny Stocks To Buy According To Insiders In December
Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.
2023-10-20 08:15:02 - Benzinga
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-08-03 07:30:00 - GlobeNewsWire
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the 2023 Canaccord Healthcare Conference on Thursday, August 10, 2023 at 11:00 a.m. ET in Boston.
2023-05-31 07:30:00 - GlobeNewsWire
Generation Bio to Present at the 2023 Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2023 Jefferies Healthcare Conference Wednesday, June 7, 2023 at 1:30 p.m. EST in New York.
2023-05-10 19:45:38 - Zacks Investment Research
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.61 per share a year ago.
2023-05-09 16:15:00 - GlobeNewsWire
Generation Bio to Present at the JMP Securities Life Sciences Conference
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023 at 1:00 p.m. EST in New York.
2023-04-11 07:30:00 - GlobeNewsWire
Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare on Tuesday, April 18th at 3:00 p.m. EST.